Alnylam Pharmaceuticals Inc
Biotechnology
Alnylam Pharmaceuticals Inc (ALNY) Stock News
The latest ALNY headlines and market coverage — 3 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm
Law firm Bragar Eagel & Squire is investigating Alnylam Pharmaceuticals for potential federal securities law violations following the company's July 30, 2026 announcement of a $200 million reduction in TTR product sales guidance. The guidance cut, attributed to normalization of growth after initial market launch, triggered a 28.35% intraday stock price decline. The firm is seeking stockholders who suffered losses to participate in potential litigation.
- GlobeNewswire Inc.·
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is investigating Alnylam Pharmaceuticals for possible federal securities law violations. On July 30, 2026, Alnylam lowered its TTR product sales guidance by approximately $200 million due to slower-than-expected growth in the ATTR-CM market after initial pent-up demand was satisfied. The announcement triggered a 28.35% intraday stock decline, causing investor losses.
- GlobeNewswire Inc.·
ALNYLAM PHARMACEUTICALS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Law firm Kirby McInerney LLP is investigating potential securities fraud claims against Alnylam Pharmaceuticals following the company's announcement on July 30, 2026, that it lowered TTR product sales guidance by approximately $200 million due to normalization of growth in the ATTR-CM market after satisfying pent-up demand. The stock fell 28% ($81.14 per share) to $205.48 on the news.